Alvotech income statement

In fiscal 2025, Alvotech reported revenue of $586m, up 19.7% on the year before, operating income of $78.2m (a 13.3% margin) and net income of $27.9m, or $0.10 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Alvotech: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	67	37	83	91	490	586
Cost of revenue	—	0	64	161	185	236
Gross profit	—	37	19	−69	304	351
Research and development	148	191	181	211	171	184
Operating income	−138	−235	−346	−355	70	78
Interest expense	97	113	77	133	154	137
Income before tax	−292	−149	−552	−651	−218	136
Income tax	−122	−48	−38	−99	14	108
Net income	−170	−102	−514	−552	−232	28
Diluted EPS	−$1.82	−$0.92	−$2.60	−$2.43	−$0.87	$0.10
Diluted shares (average)	94m	111m	198m	227m	268m	291m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ALVO vs EBS ALVO vs TVTX ALVO vs AMPH ALVO vs INVA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Alvotech's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alvotech.